Highest-materiality recent filing
Filana shareholders approve 2018 Omnibus Incentive Plan amendment; authorized shares increased to 9M
Shareholders approved Amendment No. 2 to the 2018 Omnibus Incentive Plan, increasing authorized shares from 5M to 9M (4M added).
Filana Therapeutics Q1 net loss $10.3M; cash $86.6M, clinical hold on TSC program remains
Net loss of $10.3M ($0.21 per share) vs $23.4M loss in Q1 2025.
Filana Therapeutics board member Michael O'Donnell resigns effective at 2026 annual meeting
Michael O'Donnell notified Filana's Board of his resignation on April 22, 2026.
Net loss $91.0M ($1.88/share) vs $24.3M ($0.53) in 2024; cash $95.5M at Dec 31, 2025.
Cassava Sciences renames to Filana Therapeutics; new ticker FLNA effective March 11
Company changed legal name to Filana Therapeutics, Inc. effective March 10, 2026.
DOJ closes inquiry into Cassava Sciences; ends all government investigations
DOJ Fraud Section closed previously-disclosed inquiry into research misconduct allegations.
Cassava Sciences settles securities class action for $31.25M
Company to pay $31.25M into escrow in January 2026 to settle consolidated securities class action.
Cassava Sciences amends 8-K to report Dawn Bir appointed to Compensation Committee
Dawn C. Bir appointed to Compensation Committee effective December 18, 2025.
FDA letter on Dec 15, 2025 places proposed simufilam TSC-related epilepsy trial on full clinical hold.
Cassava Sciences awards CEO Barry $355K bonus tied to simufilam TSC epilepsy exploration
Board approved cash bonuses for 2025: CEO Richard Barry $355,000, CFO Eric Schoen $215,000.
Cassava Sciences receives FDA request for additional info on simufilam IND for TSC-related epilepsy
Submitted IND for simufilam in tuberous sclerosis complex (TSC)-related epilepsy.
Cassava Sciences Q3 net loss $10.8M; advances simufilam for TSC epilepsy
Net loss of $10.8M ($0.22/share) vs $27.9M loss ($0.58) in Q3 2024; cash $106.1M.
Federal court dismisses criminal indictment against Cassava's former collaborator Dr. Wang
U.S. District Court for Maryland granted unopposed motion to dismiss with prejudice all charges against Dr. Hoau-Yan Wang.
Cassava appoints Dawn Bir to board; plans simufilam TSC-epilepsy study in H1 2026
Dawn Bir appointed as Class I director effective Oct 21, 2025; board expanded to eight members.
Cassava Sciences files 8-K with corporate presentation; no specific facts extracted
Company furnished a corporate presentation dated September 2025 as Exhibit 99.1.
Net loss $44.2M ($0.92 per share) vs net income $6.2M in Q2 2024.
Cassava Sciences Reports Positive Preclinical Results for Simufilam in TSC-Related Epilepsy Model
Simufilam attenuated seizure progression with significant dose-response in Tsc1 conditional knockout mouse model of TSC-related epilepsy.
Cassava Sciences simufilam reduces seizures 60% in TSC mouse model; H1 2026 clinical trials planned
Preclinical data: simufilam reduced seizure frequency by 60% vs. vehicle in focal onset seizure mouse model (p<0.0001).
Cassava shareholders reject board declassification; director pay raised
Proposal to reduce board classification from 3 to 2 classes failed despite 91% of votes cast in favor, lacking 66 2/3% of outstanding shares.
Cassava reports Q1 net loss of $23.4M, discontinues Alzheimer's program, pivots to TSC epilepsy
Net loss of $23.4M vs net income of $25.0M in Q1 2024; cash and equivalents $117.3M, no debt.
Cassava Sciences CMO retiring; new COO/Legal and SVP Clinical Dev appointed
CMO Dr. James Kupiec retiring effective May 9, 2025.
Cassava Sciences simufilam Phase 3 trial fails all endpoints; Alzheimer's program discontinued
Phase 3 REFOCUS-ALZ failed all co-primary, secondary, and biomarker endpoints.
Cassava Sciences amends bonus plan; ties CEO payout to FDA approval of simufilam
Amendments require Chairman/President/CEO bonus only if FDA approves simufilam, except in Merger Transaction.
Cassava Sciences Reports 2024 Financial Results and Provides Business Update
Net loss of $24.3 million ($0.53 per share) in 2024 vs $97.2 million in 2023; cash and equivalents $128.6 million with no debt.
Cassava Sciences licenses Yale simufilam patent for TSC-related seizures; up to $4.5M milestones
Exclusive worldwide license to issued US method of treatment patent (US 12,186,307) for simufilam in TSC-related epilepsy and other indications.
Cassava cuts workforce 33% after Phase 3 miss; REFOCUS-ALZ results due Q1/Q2 2025
Workforce reduction of 10 employees (33%) with ~$0.4M severance costs in Q1 2025.
Cassava Sciences simufilam Phase 3 Alzheimer's trial misses all endpoints; studies halted
Simufilam failed to meet co-primary endpoints: ADAS-COG12 delta -0.39 (p=0.43), ADCS-ADL delta 0.51 (p=0.40).
Cassava Sciences reports Q3 net loss $27.9M; RETHINK-ALZ top-line data expected by end-2024
Net loss $27.9M ($0.58 per share) vs $25.7M ($0.61) in Q3 2023; cash $149M at Sep 30, 2024.
Cassava Sciences agrees to $40M SEC settlement; ReTHINK Phase 3 top-line due by year end
Agreed to pay $40M civil penalty to SEC for negligent disclosures related to Phase 2b study; DOJ not expected to charge company.
Cassava Sciences discloses CEO Richard Barry compensation: $675k base, 600k options at $27.42
Base salary $675,000, retroactive to July 15, 2024; annual bonus target 60% of base salary.
Cassava Sciences settles SEC probe for $40M; DOJ not expected to charge company
Agreed to pay $40M civil penalty without admitting or denying SEC allegations of negligence-based disclosure violations.
Cassava Sciences enters consulting agreement with former CEO Remi Barbier
Consulting agreement effective Sep 13, 2024 for one year, with potential one-year extension.
Cassava Sciences appoints Rick Barry as CEO; Claude Nicaise becomes Chairman
Richard Barry named CEO effective September 6, 2024; previously Executive Chairman and director since June 2021.
Cassava Sciences corrects diluted EPS for H1 2024 to ($0.28) from ($1.72)
Corrected diluted EPS for six months ended June 30, 2024 is $(0.28), not $(1.72) as originally reported.
Cassava Sciences reports Q2 net income, $40M SEC loss contingency, Phase 3 readout timeline
Q2 net income $6.2M vs net loss $26.4M in 2023, driven by non-cash warrant gain.
Cassava Sciences Executive Chairman outlines Phase 3 trial timelines and transparency pledge
First Phase 3 simufilam trial (804 patients) to read out by Dec 2024; second by June 2025.
Settlement modifies CEO Remi Barbier's $74.9M bonus: payment requires FDA approval of simufilam or recalculation upon sale.
Cassava Sciences CEO Remi Barbier resigns; Rick Barry named Executive Chairman; CEO search begins
CEO/President Remi Barbier resigns effective Sep 13, 2024; also resigns as Chairman and Board member immediately.
Cassava discloses potential unblinding in Phase 2b study; collaborator indicted by DOJ
DOJ indicted Dr. Wang for allegedly causing false statements to NIH about simufilam; company terminated his consulting.
CEO Remi Barbier receives $500k discretionary cash bonus.
Quorum of ~62% (26,979,468 shares) represented at May 9, 2024 annual meeting.
Cassava Sciences Q1 net income $25M; Phase 3 Alzheimer's trials on track with >1,900 patients
Net income of $25.0M vs net loss $24.3M in Q1 2023; non-cash warrant gain drove the swing.
Cassava Sciences raises over $125M from warrant exercises; ~5.7M shares at $22
Gross proceeds over $125M from cash exercises of warrants; ~5.7M common shares issued at $22.00 per share.
SAVAW warrants last trade May 2; final exercise May 6 at $33 for 1.5 shares
Last trading day for SAVAW warrants on NASDAQ: end of day May 2, 2024.
May 6, 2024 at 5pm ET is last day to exercise warrants (distributed Jan 3); unexercised warrants redeemed May 7 for $0.001 each.
Cassava Sciences reports FY2023 net loss of $97.2M; Phase 3 topline data expected year-end 2024
Net loss $97.2M ($2.32/share) vs $76.2M ($1.90) in 2022; R&D expenses $89.4M.
Cassava Sciences: simufilam shows stable ADAS-Cog in mild Alzheimer's over 24 months
Mild Alzheimer's patients on continuous simufilam (n=47) averaged 0.07 point ADAS-Cog change (±1.51 SE) from baseline to month 24.
Distribution of warrants to holders of record as of Dec 22, 2023, at ratio of 4 warrants per 10 common shares.
Stockholders of record Dec 22, 2023 receive 4 warrants per 10 shares, free of charge; distributed Jan 3, 2024.
Cassava Sciences expands board to 9 with three new directors
Appointed Dr. Claude Nicaise, Pierre Gravier, and Robert Anderson, Jr. effective Dec 6, 2023.
On April 18, 2025, Mr. Cook, previously our Senior Vice President and General Counsel, was appointed Chief Operating and Legal Officer of the Company.
On April 15, 2025, James W. Kupiec, M.D. informed Cassava Sciences, Inc. (the “Company”) of his intent to retire and tendered his resignation as the Company’s Chief Medical Officer, effective as of May 9, 2025.
On September 9, 2024, Cassava Sciences, Inc. (“Cassava” or the “Company”) announced that the Company’s Board of Directors has concluded its search for a Chief Executive Officer (“CEO”) and has appointed Richard (Rick) Barry as the Company’s CEO.
the Board has appointed Claude Nicaise, M.D., as its Chairman.
In addition, on July 15, 2024, the Company’s Board of Directors (the “ Board ”) accepted Mr. Barbier’s resignation as Chairman of the Board and from board membership, effective immediately.
On July 15, 2024, Remi Barbier, President and Chief Executive Officer of Cassava Sciences, Inc. (the “ Company ” or “ Cassava ”) resigned from the Company, effective as of September 13, 2024
On July 15, 2024, Richard J. Barry, an independent director and currently the Chair of the Company’s Audit and Nominating & Governance Committees, was appointed by the Board as its Executive Chairman.
Max materiality 1.00 · Median 0.68 · Most common event other_material